#United States #New York #biotechnology #Rigel Pharmaceuticals #Jefferies Conference

Rigel Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a prominent player in the biotechnology sector, is gearing up to present at the highly anticipated Jefferies Global Healthcare Conference. This significant event will take place on June 4, 2025, at 12:50 p.m. ET in New York City, where Raul Rodriguez, the President and CEO of Rigel, is expected to deliver an in-depth overview of the company’s recent advancements and strategic direction.

What to Expect During the Presentation

During his presentation, Rodriguez will outline Rigel's commitment to developing innovative therapies targeted at hematologic disorders and various forms of cancer. Rigel Pharmaceuticals has been making headlines for its pioneering research and groundbreaking treatments, aimed at significantly enhancing patient outcomes. With cancer and blood-related diseases on the rise, the work being done at Rigel plays a crucial role in the healthcare landscape.

To ensure that interested participants can easily follow the presentation, the company will be hosting a live webcast. Individuals can access the broadcast through the Investor Relations section of Rigel's website. It is recommended that viewers connect to the website beforehand to facilitate any necessary software downloads, ensuring a seamless viewing experience.

About Rigel Pharmaceuticals

Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals has built a solid reputation as a biotechnology company focused on addressing unmet medical needs. The firm specializes in the discovery, development, and commercialization of novel therapeutics tailored for patients suffering from severe diseases such as hematologic disorders and different types of cancer. Rigel's continuously growing pipeline highlights its dedication to enhancing lives through innovative medical solutions.

For the latest updates on their marketed products and ongoing clinical trials, interested parties are encouraged to check out Rigel’s official website at www.rigel.com.

Conclusion

The Jefferies Global Healthcare Conference heralds an invaluable opportunity for stakeholders in the healthcare sector and potential investors to engage with Rigel Pharmaceuticals' ambitious vision. With an unwavering commitment to patient care and a focus on breakthrough advancements, Rigel is poised to shape the future of biopharmaceutical innovation.

For additional inquiries, media representatives and investors may contact Rigel Pharmaceuticals at (650) 624-1232. For media inquiries, the company has partnered with David Rosen of Argot Partners, who can be reached at (646) 461-6387.

As Rigel Pharmaceuticals takes to the stage, the world will be watching closely, waiting to see the next steps in the fight against cancer and blood disorders.